about
Vaccination of the immunocompromised childRole of Toll-like receptors in adjuvant-augmented immune therapies.Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer typesMessenger RNA-based vaccines: progress, challenges, applicationsA crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapyHIV and the chemokine system: 10 years later.Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infectionToward Standardizing a Lexicon of Infectious Disease Modeling TermsDifferences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discoveryRabies virus glycoprotein as a carrier for anthrax protective antigenVersatile virus-like particle carrier for epitope based vaccinesType 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data.Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cellsExploring peptide mimics for the production of antibodies against discontinuous protein epitopes.Early infections by myxoma virus of young rabbits (Oryctolagus cuniculus) protected by maternal antibodies activate their immune system and enhance herd immunity in wild populations.Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 miceProtection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.Parasite Carbohydrate Vaccines.Clonotypic composition of the CD4+ T cell response to a vectored retroviral antigen is determined by its speed.A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.The manipulation of immunity. Conference on from allergy to cancer: new perspectives for therapeutic vaccinationPeripheral development of B cells in mouse and man.Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost studyTransfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Vaccines against malaria-still a long way to go.Influenza virus-specific neutralizing IgM antibodies persist for a lifetime.Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.Impact of viral drift on vaccination dynamics and patterns of seasonal influenza.Characterization of an effective CTL response against HIV and SIV infections.Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth diseaseSomatostatin Improved B Cells Mature in Macaques during Intestinal Ischemia-Reperfusion.On 'reactivity' versus 'tolerance'.Does malaria suffer from lack of memory?The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.Fostering of advanced mutualism with gut microbiota by Immunoglobulin A.Transgenerational effects enhance specific immune response in a wild passerineDendritic cells as therapeutic vaccines against cancer.Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.
P2860
Q22305944-48D9FE8F-C308-468E-AFE7-1D0ED9DA0982Q25257661-8D2D3136-0AE8-46B9-AB70-EE8720CC2DF5Q26745894-C53E245C-1F8E-4AF5-BDF2-163156E77D9EQ27012738-551F5AA2-3D1A-4A26-AB88-B5DB5F5EF577Q27314576-2FB51F23-EBE3-4C6C-A0EE-4928F5346258Q27473020-95F9724F-09E0-43F2-B34C-2143DDEEDE62Q27480404-5B8B158B-2320-414D-A64D-ECF2578436B7Q28067058-8F64F5BF-10EE-4546-B2BF-F22E18FA299FQ28077110-5A7FC388-D535-45A3-93DE-64DA87FD7749Q28391261-672A31E9-756D-48D7-8361-B540435175F4Q28748358-213D8913-1382-4DDD-9025-070A5CF33226Q30245271-73E63EB1-04F1-41FF-95E3-5172FE0E3E3FQ33450551-9168EE53-D9AD-4835-BC2D-5B144F5A0CC4Q33520582-7F5C4BDB-D5B9-409C-93F0-FE752FF8C969Q33585153-F2589D02-4CEA-442A-934E-9A04137F78BAQ33602804-892407E7-2021-49C2-AD50-E6A7DE9EBDB3Q33727055-32A71736-D9B0-4BA8-93A6-1928CFFA4BC8Q33736534-E66CC6D4-CA51-49D0-A77E-40B8D616D934Q33785863-034A93CF-BE51-49A1-A501-C480B56E6D98Q33993393-64063D5B-98C3-46D5-B8A9-7E95B44FAF22Q34047445-DB10F643-A8F3-4A79-B956-5CECA222B045Q34059945-A2143B2C-C51B-4A05-AE06-23930BE96B7BQ34166187-6C64C8A8-C281-4B46-ABB9-063398A9C7C9Q34298533-03954591-B8C8-4295-9476-052070433921Q34312108-F4195A8A-AD70-4B6C-BBA2-6D1E9245447BQ34391256-2F871926-8DF7-4EAA-9D79-9C9A40A9F290Q34556687-F9D0528B-7AFD-4FAB-A72D-9B28D52D6B09Q34593000-A2F03EC3-45D5-4EBE-A1BA-5651685E8321Q35043107-C9B94933-8448-459F-865D-EF0264B11934Q35065311-70F99EC2-2370-42DD-898A-661D2E97035EQ35250925-4A23A604-4C0E-45FF-A60A-018EC912E629Q35345853-B0DF2F2E-F879-4E62-BF15-ABB374D7D6AFQ35723929-4DCD83D7-DB38-4CBD-A140-9E4E0A599472Q35850625-B20EA726-9A1A-43EE-89BD-B558D6D657E8Q35884250-FF524B51-3CE5-4E8F-A0FE-074972E67759Q35884264-5D3679CB-EB2B-44E0-BABC-8D6345A19C49Q35920077-501326BB-4963-41D4-A77C-3C67434DBFE8Q35986896-264DF878-41EF-408F-AA88-0FBFA74B1E05Q36085614-7D3D197F-5DF7-4B01-A9A0-5E5DF9672BF7Q36242828-065CD72A-E6C9-4AAC-BCA0-DF68173CBBB8
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
On natural and artificial vaccinations.
@ast
On natural and artificial vaccinations.
@en
type
label
On natural and artificial vaccinations.
@ast
On natural and artificial vaccinations.
@en
prefLabel
On natural and artificial vaccinations.
@ast
On natural and artificial vaccinations.
@en
P1476
On natural and artificial vaccinations.
@en
P2093
Rolf M Zinkernagel
P304
P356
10.1146/ANNUREV.IMMUNOL.21.120601.141045
P577
2001-12-19T00:00:00Z